SK Capital Partners Acquires Majority Stake in SEQENS
December 16, 2021
Funds advised by SK Capital Partners acquired a majority shareholding in SEQENS, investing alongside Bpifrance, Nov Santé, Mérieux Equity Partners, Ardian, Eximium and SEQENS' management. The deal includes the integration of Wavelength Pharmaceuticals into SEQENS and the prior divestiture of certain non-core mineral specialties assets; SEQENS emerges as a strengthened pharmaceutical CDMO with ~€1.1bn revenue and ~3,200 employees.
- Buyers
- SK Capital Partners, Bpifrance, Nov Santé, Mérieux Equity Partners, Ardian, Eximium, SEQENS management team
- Targets
- SEQENS
- Sellers
- Eurazeo
- Industry
- Pharmaceuticals
- Location
- Auvergne-Rhône-Alpes, France
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
Summa Equity Acquires Majority Stake in Sengenics
October 14, 2020
Biotechnology
Summa Equity Fund II has acquired a majority stake in Sengenics, a functional proteomics company that commercialises the KREX technology for full‑length, correctly folded protein production and autoantibody detection. The investment will support Sengenics' product development, global expansion and accelerated commercial adoption across pharma, academic research and diagnostics.
-
Keensight Capital Acquires Majority Stake in Symeres from Gilde Healthcare
May 25, 2021
Healthcare Services
Keensight Capital will acquire a majority stake in Symeres, a leading European small-molecule CRO and CDMO, from Gilde Healthcare with management co-investing. The investment will fund organic growth and further M&A to expand Symeres' drug discovery, development and manufacturing capabilities across Europe and globally.
-
SK Capital Partners Acquires IPACKCHEM Group SAS
April 6, 2021
Manufacturing
SK Capital Partners, a New York-based private investment firm focused on specialty materials and chemicals, has completed the acquisition of IPACKCHEM Group SAS, a Paris-headquartered manufacturer of sustainability-oriented barrier plastic packaging for the crop protection and specialty chemicals markets. SK Capital said it will partner with IPACKCHEM's management to accelerate organic and acquisitive growth and expand the company's global market position.
-
Keensight Capital Acquires Majority Stake in Biovian
May 23, 2018
Biotechnology
Keensight Capital has acquired a majority stake in Biovian, a Finnish contract development and manufacturing organization (CDMO) for biopharmaceuticals, alongside the company's founders, managers and Edmond de Rothschild Equity Strategies (ERES) funds. Biovian, founded in 2003 and based in Finland with ~70 employees, provides end-to-end GMP manufacturing, development and analytical services for biologics, gene therapies and vaccines; Keensight will support scaling the business to become a leading European biologics CDMO.
-
SK Capital Partners Acquires Apotex Pharmaceutical Holdings
April 3, 2023
Pharmaceuticals
An affiliate of funds advised by SK Capital Partners has completed the acquisition of Apotex Pharmaceutical Holdings Inc. SK Capital appointed Allan Oberman as President and CEO as it looks to transform Apotex into a Canadian-based global health company; Apotex employs nearly 8,000 people and sells affordable medicines in over 100 countries.
-
Equistone Partners Europe Acquires Majority Stake in Omnicare
August 14, 2019
Pharmaceuticals
Equistone Partners Europe has agreed to acquire a majority stake in Omnicare, a German pharmaceutical wholesaler specializing in distribution of finished medicines to compounding pharmacies for patient-specific oncology treatments. The seller is a consortium of shareholders that will retain a stake; Omnicare’s management, led by Oliver Tamimi, will remain in place and the deal (terms undisclosed) is expected to close in Q4 2019.
Track M&A activity that matters to you
Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.